In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The closing price of Lexaria Bioscience Corp (NASDAQ: LEXX) was $0.54 for the day, down -2.89% from the previous closing price of $0.56. In other words, the price has decreased by -$2.89 from its previous closing price. On the day, 0.59 million shares were traded. LEXX stock price reached its highest trading level at $0.562 during the session, while it also had its lowest trading level at $0.49.
Ratios:
Our analysis of LEXX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.32 and its Current Ratio is at 2.32. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jul 29 ’25 when BUNKA CHRISTOPHER bought 15,600 shares for $0.92 per share. The transaction valued at 14,375 led to the insider holds 270,012 shares of the business.
BUNKA CHRISTOPHER bought 11,900 shares of LEXX for $10,866 on Jul 30 ’25. The Director now owns 281,912 shares after completing the transaction at $0.91 per share. On Jul 29 ’25, another insider, McKechnie William Edward, who serves as the Director of the company, bought 5,000 shares for $0.91 each. As a result, the insider paid 4,532 and bolstered with 18,191 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LEXX now has a Market Capitalization of 13533794 and an Enterprise Value of 9841310. For the stock, the TTM Price-to-Sale (P/S) ratio is 19.07 while its Price-to-Book (P/B) ratio in mrq is 3.56. Its current Enterprise Value per Revenue stands at 13.941 whereas that against EBITDA is -0.852.
Stock Price History:
The Beta on a monthly basis for LEXX is 0.59, which has changed by -0.75652176 over the last 52 weeks, in comparison to a change of 0.17673707 over the same period for the S&P500. Over the past 52 weeks, LEXX has reached a high of $2.43, while it has fallen to a 52-week low of $0.46. The 50-Day Moving Average of the stock is -44.04%, while the 200-Day Moving Average is calculated to be -48.52%.
Shares Statistics:
LEXX traded an average of 652.27K shares per day over the past three months and 2709280 shares per day over the past ten days. A total of 24.89M shares are outstanding, with a floating share count of 23.39M. Insiders hold about 6.00% of the company’s shares, while institutions hold 6.90% stake in the company. Shares short for LEXX as of 1765756800 were 618196 with a Short Ratio of 0.95, compared to 1763078400 on 651519. Therefore, it implies a Short% of Shares Outstanding of 618196 and a Short% of Float of 2.9000001.
Earnings Estimates
The market rating for Lexaria Bioscience Corp (LEXX) is a result of the insights provided by 1.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.12, with high estimates of -$0.12 and low estimates of -$0.12.
Analysts are recommending an EPS of between -$0.34 and -$0.46 for the fiscal current year, implying an average EPS of -$0.4. EPS for the following year is -$0.75, with 2.0 analysts recommending between -$0.33 and -$1.17.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 1 analysts. It ranges from a high estimate of $100k to a low estimate of $100k. As of. The current estimate, Lexaria Bioscience Corp’s year-ago sales were $183.92kFor the next quarter, 1 analysts are estimating revenue of $100k. There is a high estimate of $100k for the next quarter, whereas the lowest estimate is $100k.
A total of 2 analysts have provided revenue estimates for LEXX’s current fiscal year. The highest revenue estimate was $1.17M, while the lowest revenue estimate was $400k, resulting in an average revenue estimate of $784.5k. In the same quarter a year ago, actual revenue was $705.92k
